CA-NEXON-AMERICA-INC
14.5.2020 05:02:10 CEST | Business Wire | Press release
The highly-anticipated free to play kart racing game, KartRider: Drift , will hold its second Closed Beta starting June 3, 2020 via the Nexon Launcher, Steam, and Xbox One, including Xbox One X delivering cross-platform play. Players can register here for a chance to join the second Closed Beta starting today!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005906/en/
Players invited to the second Closed Beta will receive an acceptance email, and they can pre-download the game starting on June 1, 2020 at 7 p.m. PDT. Players who participated in the first Closed Beta will automatically be included.
During the Closed Beta period, players will be introduced to a new character — Diz, as well as new skins for existing characters, plus additional karts and tracks. The Closed Beta will also showcase new functions such as Racing Pass and a new Racing School single-player mode, where new and experienced players can improve their racing skills.
Customization will be a huge part of this Closed Beta with the preview of the new wraps, which allows racers to paint their karts and create unique designs for maximum personalization. Participants will also have access to kart upgrades including choice of license plate and can decorate their karts with a lineup of new accessory balloons and character emotes.
Players will also see a revamped User Interface with a new HUD and contextual rear view mirror. The matchmaking experience has also been improved as players will be queued based on their performance in the tutorial. Driving physics of the game have also been improved since the first Closed Beta for a better racing experience.
To reward players who log in during the Closed Beta, special login rewards including a Turbo Tortoise Kart, Bunny Buggy Kart, Simian Scrapper Kart, and Deuce Coupe Kart will be unlocked. All Beta participants will also receive a White Cloud Balloon item at official launch.
Players who sign up for Closed Beta 2 at www.kartriderdrift.net will be in for a treat as KartRider: Drift has partnered with HyperX, ViewSonic and DXRacer, for an opportunity to win exclusive prizes.
KartRider: Drift’s Closed Beta will be available worldwide on the Nexon Launcher, Steam, Xbox One, including Xbox One X, with the exception of Japan, and China on console. To see a full list of available regions, please follow this link .
For more information on KartRider: Drift , visit www.kartriderdrift.net or follow @KartRiderDrift on Twitter for the latest updates and information on contests and giveaways.
Social Media: Facebook / Twitter / Instagram / Discord / Official Site
Press Assets:
About KartRider: Drift http://kartrider.nexon.net/
Launched in 2004, KartRider is a massively popular multiplayer racing franchise that boasts more than 300 million PC players. Making its debut to western audiences, KartRider: Drift takes inspiration from earlier iterations of the game, delivering competitive drift-fueled racing action, featuring different game modes, and deep character + kart customization. Available completely for free on PC Steam, Xbox One, including Xbox One X, and Nexon Launcher (PC), KartRider: Drift offers cross-platform capabilities to challenge friends regardless of the platform they choose or where they are in the world.
About Nexon America Inc. http://www.nexon.net/corporate/about-nexon/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005906/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom